Advisors Asset Management Inc. trimmed its stake in Regeneron Pharmaceuticals by 7.9%, selling 443 shares in the fourth ...

Regeneron Pharmaceuticals saw a shakeup as iA Global Asset Management trimmed its holdings by 11.7%, selling off 1,538 shares ...

Shares of Regeneron Pharmaceuticals Inc. REGN shed 1.45% to $662.62 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.22% ...

Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer - - Announced ...

Regeneron Pharmaceuticals Inc. closed 45.10% below its 52-week high of $1,211.20, which the company reached on August 27th.

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other oversold blue chip stocks. The uncertainty related to the tariff ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the investigational use of Dupixent in adults with moderate-to-severe ...

The agreement was signed in a letter of intent March 3 to set the groundwork for whether government health programs in different provinces and territories will cover the drug's cost for patients, ...

It has been about a month since the last earnings report for Regeneron (REGN). Shares have lost about 4.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...